Condition
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials that are recruiting, at sites in 4 countries (most in China (3), Spain (1), United Kingdom (1)). 1 was first registered in the last 30 days. By phase: Phase 1 (4). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1New in 30 days
- 4Countries
Newest Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| GN001 therapy for B-cell cancers that have come back or not responding | Phase 1 | Kunming, Yunnan and 1 other locations | Recruiting | Nov 2, 2026 |
| Evaluating YK012 for treating relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Beijing, Beijing Municipality | Recruiting | Aug 22, 2024 |
| Evaluating a new treatment for relapsed or refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | Beijing, Beijing Municipality and 14 other locations | Recruiting | Jan 3, 2024 |
| CD19 targeted CAR T cell therapy for children with relapsed or refractory B cell leukemia and lymphoma | Phase 1 | Los Angeles, California and 13 other locations | Recruiting | Dec 15, 2023 |
All recruiting trials (4)
-
GN001 therapy for B-cell cancers that have come back or not responding
This study tests GN001, a CAR T therapy created inside the body, in adults with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia to see if it is safe and tolerable at different doses.
-
Evaluating YK012 for treating relapsed or refractory B-cell non-Hodgkin lymphoma
This study is testing a new drug called YK012 to see if it can safely help people with relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Evaluating a new treatment for relapsed or refractory B-Cell Non-Hodgkin Lymphoma
This study is testing a new immunotherapy called MK-1045 to see if it can safely help people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma.
-
CD19 targeted CAR T cell therapy for children with relapsed or refractory B cell leukemia and lymphoma
This study is testing a new CAR T cell therapy for children with tough-to-treat B cell leukemia and lymphoma to see if it can help them feel better.
Related topics
Quick answers
How many Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (3 trials), Spain (1 trial), United Kingdom (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.